ResearcherUniversity of California, San FranciscoActive in the last 2 years

Seif Elmankabadi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5106880214. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2026.111955 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Amir Ashraf · 1 shared paper, 2026 · strength 0.29
- Paper Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2026.111955 ↗
Mohamed A. Adam · 1 shared paper, 2026 · strength 0.29
- Paper Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2026.111955 ↗
Adnan A. Alseidi · 1 shared paper, 2026 · strength 0.29
- Paper Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2026.111955 ↗
Eric K. Nakakura · 1 shared paper, 2026 · strength 0.29
- Paper Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2026.111955 ↗
Kimberly Saunders Kirkwood · 1 shared paper, 2026 · strength 0.29
- Paper Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. DOI 10.1016/j.ejso.2026.111955 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.